Impel Pharmaceuticals Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Leonard S. Paolillo
- Full Time Employees
- 160
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 201 Elliott Avenue West Seattle WA United States of America 98119
- IPO Date
- Apr 23, 2021
- CIK
- 0001445499
- Website
- impelpharma.com
- Similar Companies
- Business
- Impel Pharmaceuticals Inc. was established as a commercial-stage biopharmaceutical firm, dedicated to advancing and commercializing treatments for individuals affected by central nervous system disorders across the United States. The company's innovative efforts centered around its proprietary Precision Olfactory Delivery (POD®) technology. Its primary commercial offering, Trudhesa, an upper nasal formulation of dihydroergotamine, received U.S. FDA approval in September 2021 for the acute management of migraine, with or without aura, in adults. Beyond this, Impel's pipeline included INP105, an upper nasal olanzapine formulation aimed at treating agitation and aggression in autism spectrum disorder, and INP107, an upper nasal carbidopa/levodopa formulation, which had progressed through a Phase IIa clinical trial for addressing OFF episodes in Parkinson's disease. Originally founded in 2008 and based in Seattle, Washington, the organization transitioned its name from Impel NeuroPharma, Inc. to Impel Pharmaceuticals Inc. in April 2022. However, in December 2023, Impel Pharmaceuticals Inc. filed for Chapter 11 bankruptcy protection to facilitate a structured sale process, culminating in an undisclosed buyer acquiring substantially all of its assets by February 2024.
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale
Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?
Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
Impel Pharmaceuticals Inc. (IMPL) Q4 2022 Earnings Call Transcript
Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
Impel Pharmaceuticals Inc. (IMPL) Q3 2022 Earnings Call Transcript
Impel Pharmaceuticals, Inc. (IMPL) CEO Adrian Adams on Q2 2022 Results - Earnings Call Transcript
Impel Pharmaceuticals Inc. (IMPL) Reports Q2 Loss, Tops Revenue Estimates
Impel Pharmaceuticals: Under The Radar Despite Upside Potential
Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society
Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference
Impel NeuroPharma, Inc. (IMPL) CEO Adrian Adams on Q1 2022 Results - Earnings Call Transcript
Impel Pharmaceuticals Inc. (IMPL) Reports Q1 Loss, Tops Revenue Estimates
Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference